Taysha Gene Therapies Future Growth
Future criteria checks 2/6
Taysha Gene Therapies is forecast to grow earnings and revenue by 18.9% and 42% per annum respectively while EPS is expected to grow by 33.3% per annum.
Key information
18.9%
Earnings growth rate
33.3%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 42.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 18 Apr 2024 |
Recent future growth updates
Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07We're Hopeful That Taysha Gene Therapies (NASDAQ:TSHA) Will Use Its Cash Wisely
Mar 08Taysha and UT Southwestern Medical Center launch innovation fund in gene therapy development push
Jan 13Taysha teams up with AllStripes to advance gene therapy in rare disorder
Jan 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 51 | -69 | -92 | N/A | 4 |
| 12/31/2025 | 5 | -93 | -74 | -73 | 9 |
| 12/31/2024 | 9 | -78 | -62 | -66 | 10 |
| 12/31/2023 | 15 | -112 | -80 | -73 | N/A |
| 9/30/2023 | 14 | -214 | -52 | -42 | N/A |
| 6/30/2023 | 10 | -124 | -62 | -53 | N/A |
| 3/31/2023 | 7 | -133 | -85 | -68 | N/A |
| 12/31/2022 | 3 | -166 | -113 | -88 | N/A |
| 9/30/2022 | N/A | -161 | -174 | -143 | N/A |
| 6/30/2022 | N/A | -186 | -179 | -146 | N/A |
| 3/31/2022 | N/A | -193 | -168 | -136 | N/A |
| 12/31/2021 | N/A | -175 | -139 | -117 | N/A |
| 9/30/2021 | N/A | -142 | -116 | -97 | N/A |
| 6/30/2021 | N/A | -106 | -87 | -71 | N/A |
| 3/31/2021 | N/A | -87 | -61 | -51 | N/A |
| 12/31/2020 | N/A | -60 | -40 | -31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TSHA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TSHA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TSHA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TSHA's revenue (42% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: TSHA's revenue (42% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TSHA's Return on Equity is forecast to be high in 3 years time